The mechanisms controlling the transition from neurogenesis to gliogenesis in the vertebrate CNS are incompletely understood. We identified a family of transcription factors, called NFI genes, which are induced throughout the spinal cord ventricular zone (VZ) concomitantly with the induction of GLAST, an early marker of gliogenesis. NFIA is both necessary and sufficient for GLAST induction in the VZ. Unexpectedly, NFIA is also essential for the continued inhibition of neurogenesis in VZ progenitors. This function is mediated by the requirement of NFIA for the expression of HES5, a Notch effector. However, Notch effectors are unable to promote glial-fate specification in the absence of NFIA. Thus, NFIA links the abrogation of neurogenesis to a generic program of gliogenesis, in both astrocyte and oligodendrocyte VZ progenitors. At later stages, NFIA promotes migration and differentiation of astrocyte precursors, a function that is antagonized in oligodendrocyte precursors by Olig2.
Introduction
Stem cells are uncommitted progenitors with the capacity to both self-renew and to give rise to one or more differentiated derivatives (Morrison et al., 1997) . In some stem cell lineages, such as the adult hematopoietic system, multipotent progenitors produce their various differentiated progeny concurrently (Morrison et al., 1994) . In other systems, however, multipotent stem and progenitor cells generate different types of derivatives on a defined schedule. In the developing central nervous system (CNS), neurons are generated first, followed by glia. The invariance of this developmental sequence throughout the CNS, and its conservation across vertebrate phylogeny, suggests that it involves a fundamental mechanism. Despite the importance of this ''gliogenic switch,'' however, its molecular basis is poorly understood.
The gliogenic switch is comprised of two related processes: the inhibition of neurogenesis and the activation of gliogenesis. A basic unresolved issue is the logic by which these two processes are coordinated during the switch. At one extreme, a unitary mechanism could both prevent neurogenesis and promote gliogenesis ( Figure 1A1 ), as exemplified by the glial cells-missing gene in Drosophila (Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996) . At the other extreme, a distributed mechanism could operate, in which the abrogation of neurogenesis serves a permissive function, while a distinct, positive-acting factor instructs the glial program ( Figure 1A2 ). A distributed mechanism could also involve independent processes, which are nevertheless linked in some manner ( Figure 1A3) .
A number of studies have been interpreted to suggest that inhibition of neurogenesis is sufficient to trigger the onset of gliogenesis. The Notch pathway inhibits neurogenesis in embryonic CNS progenitors (Chitnis et al., 1995) . The mechanism of this inhibition involves the induction of transcriptional repressors, such as HES genes, that prevent the expression of proneural genes, such as the neurogenins (Ngns) (reviewed in Louvi and Artavanis-Tsakonas, 2006) . Notch signaling has been shown to be necessary for the generation of glial cells, and gain-of-function manipulations of Notch and its effectors often yield an increased number of glial cells (Ishibashi et al., 1994; Ohtsuka et al., 1999; Gaiano et al., 2000; Ohtsuka et al., 2001; Satow et al., 2001; Zhou et al., 2001; Park et al., 2002; Hatakeyama et al., 2004) . However, these genetic experiments do not distinguish whether Notch signaling directly controls the gliogenic switch or rather indirectly influences this process by controlling the size of the undifferentiated progenitor pool (Androutsellis-Theotokis et al., 2006) .
The idea that the abrogation of neurogenesis is sufficient to initiate gliogenesis has received additional support from in vitro studies indicating that Ngn1, in addition to its proneuronal function (Ma et al., 1998) , actively inhibits astrogliogenesis by blocking the JAK/ STAT pathway (Sun et al., 2001; He et al., 2005) , which in turn controls the expression of GFAP (Bonni et al., 1997; Kahn et al., 1997; Nakashima et al., 1999) . According to this model, downregulation of Ngns would relieve inhibition of the JAK/STAT pathway, thereby inducing gliogenesis essentially by default. However, GFAP is a terminal astrocyte differentiation marker that is not expressed until several days after glial precursors have emigrated from the ventricular zone (VZ), where the gliogenic switch occurs. Furthermore, evidence that this mechanism controls the initial specification of the glial fate in vivo is limited. Double deletions of proneural genes increase the extent of astroglial differentiation in vivo, but precocious appearance of astrocytes was not consistently observed (Nieto et al., 2001) . Therefore, while disinhibition of the JAK/STAT pathway may be necessary for terminal astrocyte differentiation, it is not clear whether it controls the initial gliogenic switch in the VZ. Indeed, no transcription factor has been identified that is sufficient to promote the initial specification *Correspondence: wuwei@caltech.edu of the glial fate in the VZ, in vivo. The HMG box transcription factor Sox9 is required for the proper timing of gliogenesis throughout the spinal cord (Stolt et al., 2003) . However, Sox9 is not sufficient to promote gliogenesis in vivo (B.D. and D.J.A., unpublished data) .
Here we show that NFIA and NFIB, members of a family of CCAAT box element-binding transcription factors (Gronostajski, 2000) , are both necessary and sufficient to promote glial-fate specification in embryonic spinal cord progenitors, in vivo. In contrast to Notch effectors, such as HES genes, NFI genes are not sufficient to inhibit neurogenesis. Unexpectedly, however, NFIA is required for the continued inhibition of neurogenesis in VZ progenitors. This function is mediated by the requirement of NFIA for the expression of HES5, a Notch effector. However, Notch effectors are unable to promote glial-fate specification in the absence of NFIA. Thus, NFIA links the abrogation of neurogenesis to a generic program of gliogenesis, in both astrocyte and oligodendrocyte VZ progenitors.
The requirement for NFIA in the oligodendrocyte lineage is mediated by its requirement for the maintenance of expression of Olig2 (Lu et al., 2002; Zhou and Anderson, 2002) . Paradoxically, however, at later stages NFIA/ B promote terminal astrocyte differentiation. This dual and sequential role requires a mechanism to suppress NFIA function in oligodendrocyte precursors (OPs). We show that this proastrocytic function of NFIA is antagonized by Olig2, by a mechanism that likely involves direct protein-protein interactions. These data suggest that the gliogenic switch has an intrinsic astrocytic bias, upon which the oligodendrocyte fate is superimposed by Olig2.
Results

NFIA and NFIB Are Induced at the Onset of Gliogenesis throughout the Developing Spinal Cord
To identify candidate genes associated with the switch from neurogenesis to gliogenesis, we compared the gene expression profiles of Olig2 + progenitors isolated at different times spanning this developmental transition (Lu et al., 2002; Zhou and Anderson, 2002; Mukouyama et al., 2006) . Olig2-GFP + progenitors were purified by FACS from the embryonic spinal cord of Olig2-GFP knockin mice, at neurogenic stages (E9.5-E10.5) and at early gliogenic stages (E11.5-E12.5) (see Figure S1A , arrows, in the Supplemental Data available online). cRNA probes were generated from total RNA isolated from these different purified progenitor populations and hybridized to Affymetrix microarrays (see the Supplemental Experimental Procedures). Among the transcription factors induced in Olig2 + cells at the onset of gliogenesis were nuclear factor I-A (NFIA) and nuclear factor I-B (NFIB) ( Figure 1B ). These proteins are members of a family of CAATT box-binding transcription factors, whose DNA-binding domains are distinct from those of other CCAAT box element-binding proteins (C/EBPs) (Meisterernst et al., 1988; Bandyopadhyay and Gronostajski, 1994; Gronostajski, 2000) . To validate the microarray data, we performed immunostaining using antibodies specific for NFIA and NFIB ( Figures 1C-1F ), as well as in situ hybridization for NFIA and NFIB transcripts ( Figures 1G-1L) , on mouse embryo spinal cord sections between E9.5 and E12.5. Expression of NFIA and B in the VZ is first detected at E11.5-E12.5 ( Figures 1D, 1F , 1H, and 1K, arrows), coincident with the induction in the VZ of GLAST, an early astrocyte precursor (AP) marker (Shibata et al., 1997; Ogawa et al., 2005) (Figures 1G, 1H, 1J, and 1K versus Figures 1M and 1N) . Expression of NFIA/B is initially highest in more ventral regions of the VZ ( Figures 1D, 1F , and 1H, arrows) but later expands to cover the entire neuroepithelium ( Figure 1I and data not shown). NFIA/B are also transiently expressed in a subset of differentiated motoneurons at E11.5-E12.5 ( Figures 1D, 1H , and 1K, arrowheads).
Although we initially identified NFIA/B by their upregulation in Olig2 + oligodendrocyte progenitors, their induction throughout the VZ raised the possibility that they might play a more general role in early gliogenesis. To address this question, we sought to carry out in vivo gain-and loss-of-function (GOF and LOF) experiments, in the embryonic chick neural tube. As a first step, we characterized the expression of NFIA and NFIB in this avian system. As in the mouse, NFIA/B expression was not detected in the VZ at neurogenic stages (E3-E4) (Figures 1P and 1S; cf. Figures 1C and 1E) but by E5 was expressed throughout the VZ ( Figure 1Q , arrow). The induction of NFIA followed that of cHES5, a Notch effector (Fior and Henrique, 2005) , by 1-2 days . Unlike the case in mouse, the induction of NFIB expression in chick lags behind that of NFIA by w24 hr ( Figures 1Q, 1T , and 1U). As in the mouse, however, the timing of NFIA induction was coincident with the upregulation in the VZ of GLAST (Figures 1P and 1Q versus Figures 1V and 1W) , although a low level of GLAST mRNA was detectable at E4. Double-label in situ hybridization experiments confirmed that NFIA and GLAST overlap in the VZ ( Figures 1Y-1AA ), as do Olig2 and GLAST (not shown). Importantly, while neurons continue to be generated in dorsal regions of the neural tube at cE6, the expression of NFIA in these regions is mutually exclusive with that of neuronal precursor markers such as Lim1/2 (Figures S1E and S1F; yellow arrows versus white arrowheads) (Liem et al., 1995; Muller et al., 2002) . Taken together, these data indicate that the onset of NFIA induction in the VZ is correlated with the emergence of progenitors fated to become glia ( Figure 9A ) and suggest that NFIA is likely to mark such gliogenic progenitors.
Misexpression of NFI Genes Promotes Glial-Fate Specification without Repressing Neurogenesis
The observation that the onset of NFIA is tightly correlated with the upregulation of GLAST in the VZ raised the question of whether this factor plays an instructive role in the acquisition of glial identity by VZ progenitor populations. To address this question, we asked whether misexpression of an NFIA cDNA could accelerate the timing and/or increase the extent of glial differentiation in vivo. Misexpression of NFIA caused a precocious upregulation of GLAST mRNA in the VZ at E4 (Figures 2A and  2E ; arrow) and increased expression in the VZ at E5 (Figures 2B and 2F; arrow;  Figure 2AA ). Misexpression of NFIB produced a similar phenotype ( Figures 2I, 2J , 2M, and 2N, arrows). In contrast, the expression of Olig2, which is already present in the VZ prior to the induction of NFIA, was unaffected by misexpression of NFIA or NFIB ( Figures S2G and S2J) . Misexpression of NFIA did not change the timing or extent of NFIB expression (data not shown).
In addition to promoting precocious expression of GLAST in the VZ at E4, misexpression of NFIA or NFIB increased the number of GLAST + cells migrating from the VZ into the gray matter at E6-E7 ( Figures 2G, 2H , 2O, and 2P; arrows; Figure 2Y ). A similar increase was observed using FGFR3 (Pringle et al., 2003) and FABP7 (Bisgrove and Godbout, 1999) as markers of migrating APs ( Figures S2S-S2Z ). This effect was not due simply to enhanced proliferation of APs, as no change in the number of proliferating cells, as assessed by staining for PCNA, was observed (data not shown). Coelectroporation of NFIA and NFIB did not further enhance the phenotype obtained with either gene singly ( Figure 2Y and data not shown). NFIA or NFIB did not increase the number of Olig2 + or PDGFRa + migrating OPs (Figures S2I, S2L, S2O, and S2R). Thus, NFIA/B misexpression not only accelerated GLAST induction throughout the VZ but also specifically promoted AP migration into the gray matter.
Since misexpression of NFIA/B led to a precocious induction of GLAST in the VZ, we next assessed whether it concurrently repressed neuronal markers. Misexpression of NFIA or NFIB had no effect on the number of neurogenin2-(Ngn2) or NeuN-expressing cells at E5 ( Figures 2R, 2S , and 2Z and data not shown). Thus, NFIA/B can promote gliogenesis in a manner independent of any effect to inhibit neurogenesis. It has previously been shown that misexpression of Notch pathway components, which inhibit neurogenesis, can promote astroglial differentiation (reviewed in Louvi and Artavanis-Tsakonas, 2006) . To determine whether such a manipulation could phenocopy the effect of NFIA/B misexpression in this system, we coelectroporated plasmids encoding the Notch-intracellular domain (Notch ICD ) and its coactivator suppressor of hairless (SuH). As expected (Ma et al., 1996; Artavanis-Tsakonas et al., 1999; Mumm and Kopan, 2000; Zhou et al., 2001; Kageyama et al., 2005) , this manipulation strongly repressed expression of both Ngn2 and NeuN . By contrast, it did not cause an upregulation or precocious appearance of GLAST in the VZ ( Figures 2X and 2AA) . Thus, the mere inhibition of neurogenesis, via activation of Notch signaling, does not phenocopy the ability of NFIA to accelerate the induction of GLAST in the VZ. These data suggest that inhibition of neurogenesis by Notch effectors is not sufficient to trigger the gliogenic switch, prior to the appearance of NFIA.
NFIA Expression Is Necessary for the Gliogenic Switch
We next examined the requirement of NFIA/B for glialfate specification. To do this, we focused on NFIA, because its induction precedes that of NFIB in the chick. To inhibit NFIA expression, we utilized an RCAS-based shRNAi system. The effective knock-down of endogenous chick NFIA in the VZ was verified by antibody staining (Figures 3F and 3G; arrows) . Knock-down of NFIA clearly inhibited the expression of GLAST mRNA beginning on E5 ( Figures 3J and 3K , arrows). However, the low level of GLAST mRNA detectable at E4 was unaffected, despite the expression of the NFIA-shRNAi construct at this earlier stage ( Figures 3A and 3I) . A similar phenotype was observed using FGFR3, an AP marker (Pringle et al., 2003) that is expressed both prior to and following NFIA induction in the VZ ( Figures 3Q, 3R , and 3S; arrow; Figures S1B-S1D). NFIA knock-down also prevented the induction of NFIB at E6 ( Figure 3O , arrow). Thus, the NFIA-directed shRNAi prevented the expression in the VZ of multiple astroglial precursor markers.
Olig2, which marks the oligodendrocyte progenitor domain in the VZ (Lu et al., 2000; Zhou et al., 2000) , is also expressed prior to NFIA induction at E5, reflecting its earlier role in motoneuron-fate specification (Mizuguchi et al., 2001; Novitch et al., 2001) . As in the cases of GLAST and FGFR3, expression of Olig2 was unaffected by the NFIA shRNAi at E4 ( Figure 3U ) but was lost on the electroporated side at E5 and E6 (Figures 3V and 3W, arrows) . These data suggested that NFIA knock-down not only prevents the expression of astroglial precursor markers that are induced or upregulated at E5 and later (GLAST, NFIB) but also extinguishes markers of both astrocyte (FGFR3) and oligodendrocyte (Olig2) precursors, which are initially expressed at earlier stages.
The fact that the NFIA-RNAi inhibited FGFR3 and Olig2 expression after, but not before, the time of endogenous NFIA induction at E5, despite the fact that electroporation was performed several days earlier (E2), suggested that this phenotype reflects specific NFIA knock-down. To assess further the specificity of the NFIA-RNAi phenotype, two types of control experiments were performed. First, we tested a mutant NFIA shRNAi, containing four nucleotide substitutions, which had no effect on NFIA expression (Figures 3D and 3H, arrow) . This mutant NFIA-RNAi did not alter the expression of GLAST, NFIB, FGFR3, or Olig2 ( Figures 3L, 3P , 3T, and 3X; arrows). Second, the cNFIA shRNAi construct was coelectroporated with a ''rescue'' construct containing the murine NFIA (mNFIA) coding sequence, which is sufficiently divergent from the chick sequence so as not to anneal with the cNFIA-shRNAi. An HA epitope tag was included to report expression of the exogenous mNFIA protein. In regions of the VZ containing high levels of ectopic HA-mNFIA (white arrow, Figure 3Z ), inhibition of GLAST, FGFR3, and Olig2 by the cNFIA-shRNAi was suppressed (black arrows, Figures 3AA and 3BB ; white arrow, Figure 3CC ). Conversely, in regions of the VZ that lacked sufficiently high levels of ectopic HA-mNFIA expression ( Figure 3Z , green arrowhead), expression of GLAST and FGFR3 was still inhibited by the cNFIA-shRNAi ( Figures 3AA and 3BB , green arrowheads). Taken together, these three lines of evidence strongly suggest that knock-down of endogenous NFIA is responsible for the reduction of GLAST, FGFR3, and Olig2 caused by the cNFIA-shRNAi.
NFIA Is Necessary for Progenitor Maintenance in the VZ during the Gliogenic Phase
The foregoing results led us to investigate whether the maintenance of other VZ progenitor markers, which like Olig2 are expressed throughout the neurogenicgliogenic transition, becomes dependent on NFIA after E5. Such markers include Pax6, Pax7, and Sox9. In embryos electroporated with the NFIA-shRNAi, there was a 60% reduction in the number of Pax6-expressing cells at E5, but not at E4 ( Figures 4A, 4C , and 4T). A further reduction was seen at E6 (data not shown). There was also an w40% reduction in the number of Sox9 + cells at E5 ( Figure 4O , green nuclei; Figure 4W and Figures S3F-S3J and S3L). A reduction in Pax7 expression was also observed, although this did not become apparent until E6 ( Figures S3A-S3E and S3K) . In all cases, the loss of markers was not observed in embryos electroporated with the mutant RNAi (Figures 4B and 4N ; Figures S3B, S3G, S3D, and S3I).
One possible explanation for the loss of multiple VZ markers in the absence of NFIA is cell death. The total number of Topro-3 + nuclei on the NFIA shRNAi-electroporated side was reduced by 40% at E5 (Figures 4G and  4U ). In addition, the expression of activated caspase3, a marker of apoptosis (Villa et al., 1997; Thornberry and Lazebnik, 1998), was clearly elevated on the electroporated side of the neural tube at E5, compared to the contralateral control side ( Figures 4K and 4V ). Elevated levels of activated caspase3 were not observed in NFIA shRNAi-electroporated embryos at E4 (Figures 4I and 4V) or in E5 embryos electroporated with the control (mutant) NFIA-shRNAi ( Figure 4J ). Together, these data indicate that NFIA knock-down specifically promotes gradual apoptosis in the VZ, beginning on E5.
The initial loss of marker expression observed in the VZ of NFIA knock-down embryos is not, however, due to apoptosis, as indicated by two lines of evidence. First, if marker loss were due exclusively to cell death, then all markers at a given position along the D-V axis should be coordinately extinguished. However, this is not the case: at ventral levels of the VZ, double-labeling for Sox9 and Olig2 indicates that these two markers are lost to significantly different extents in NFIA-shRNAi embryos, even though all Olig2 + cells are Sox9 + ( Figures 4O and 4W ). Second, coelectroporation of the NFIA-RNAi with the antiapoptotic protein p35 ( Figures 4Q and 4R ) (Miller, 1997; Araki et al., 2000) reduced the number of activated caspase3-expressing cells (Figure 4K versus Figures 4L and 4V) and restored the number of Topro3 + nuclei in the VZ ( Figure 4G versus Figures 4H and 4U ), but did not restore the normal expression of Pax6, Olig2, and Sox9 ( Figure 4C versus Figures 4D, 4T , and 4O versus Figures  4P and 4W) . Similarly, the loss of GLAST expression caused by NFIA knock-down was not restored by inclusion of p35 ( Figures 4S and 4X) . Taken together, these data indicate that NFIA is not only required for the induction of glial precursor markers in the VZ, but also for the maintenance of a battery of neural progenitor markers, whose expression is initiated several days before NFIA itself is induced.
Genetic Uncoupling of NFIA Function in Gliogenesis and Progenitor Maintenance
In the course of staining NFIA-shRNAi embryos with antibodies to the pan-neuronal marker NeuN, we noticed numerous NeuN-positive cells intercalated into the neuroepithelium on the electroporated side ( Figures 5A, 5B , and 5K; Ep), while on the contralateral control side such cells were separated from the ventricle by the VZ (Figure 5A , 5B, and 5K; Con). These observations could indicate a conversion of VZ progenitors to newly differentiated neurons or a migration into the VZ by previously differentiated neurons. Active neurogenesis can be assessed by the incorporation of BrdU into dividing neuronal precursors. Therefore, we performed a BrdU pulselabeling experiment at E5 in NFIA-shRNAi embryos ( Figure 5X ). In such embryos, numerous BrdU + /NeuN + cells were observed on the electroporated side, while practically none were present on the contralateral control side (Figures 5E-5G, arrows; Figure 5Y ). These data suggest that, while NFIA is not sufficient to inhibit neurogenesis when misexpressed, it may nevertheless be required for the inhibition of neurogenesis in the VZ. We next sought to delineate the mechanism by which NFIA is required to inhibit neurogenesis. Figures 5C and 5D ). These data raised the possibility that NFIA might be required for the expression of one or more components of the Notch signaling pathway. Because HES proteins are the most proximal inhibitors of neurogenesis in the Notch pathway, we investigated whether NFIA is required for the expression of HES genes in the VZ (Ishibashi et al., 1995; Hatakeyama et al., 2004) . Knock-down of NFIA (in the presence of p35) led to a clear loss of cHES5 expression (Figure 5H, arrow; Figure 5Z ). These data suggested that the requirement of NFIA for the inhibition of neurogenesis might be explained by its requirement for the expression of HES genes or of other Notch pathway elements.
To investigate further this hypothesis, we asked whether constitutive expression of Notch pathway components could rescue the NFIA-RNAi phenotype in the VZ. To this end, we coelectroporated the NFIA-shRNAi construct together with either a combination of Notch ICD and SuH or with a rat-Hes cDNA. Both Notch ICD /SuH and Hes were able to suppress the ectopic VZ neurogenesis caused by NFIA knock-down ( Figures 5K, 5P , and 5U), without affecting the loss of NFIA itself ( Figures 5I, 5N , and 5S). Strikingly, Notch ICD /SuH and Hes were also both able to restore expression of the progenitor markers Olig2, Sox9, and Pax6 ( Figures 5L, 5Q , 5V, and 5BB; Figures S4A-S4D ). They also prevented the cell death caused by NFIA knock-down in the absence of p35 (data not shown). However, constitutive Notch pathway activation did not prevent loss of the glial progenitor marker GLAST in the VZ ( Figures 5M, 5R , 5W, and 5AA). These data reveal a genetic uncoupling between the roles of NFIA in progenitor maintenance and in glial-fate specification. Notch effectors are sufficient to bypass the requirement for NFIA in the former function, but not in the latter.
NFI Genes Promote the Progression of Astrocyte Differentiation As described earlier, misexpression of NFIA not only accelerates and augments the expression of GLAST in the VZ but also causes precocious and increased emigration of APs into the gray matter ( Figures 2G, 2H , 2O, and 2P; Figure S2 ). This latter phenotype raised the question of whether NFIA has a later function in APs. To investigate this possibility, we first examined whether NFI genes continue to be expressed by migrating APs. In E10 chick embryos, we observed numerous NFIA-and NFIB-expressing cells in the gray matter that coexpressed GLAST or FGFR3 (Figures S5A-S5D) . Similarly, in the E15.5 and E18.5 mouse spinal cord, NFIA/B are expressed in cells that appear to be migrating from the VZ into the gray matter ( Figures 6A-6D, arrows) , and many such cells coexpress s100b and GFAP, two later-appearing astrocyte markers ( Figures 6E-6H , arrows). By E18.5, 80%-85% of GFAP + cells coexpressed NFIA or NFIB ( Figure 6I and data not shown).
It has been previously reported that NFIA-and NFIBdeficient mice exhibit decreased levels of GFAP mRNA expression in the adult brain, as measured via qRT-PCR (das Neves et al., 1999; Steele-Perkins et al., 2005). Similarly, in E18.5 NFIA 2/2 and NFIB 2/2 embryonic spinal cord, there was an w70% and w50% decrease in the levels of GFAP expression, respectively, as measured by immunostaining ( Figures 6J-6M and 6R ). This reduction in GFAP expression is not due to cell death or cell loss, because there was no change in the total number of cells or in the number of astrocytes, as determined by expression of the complementary NFI protein ( Figures 6N-6Q and 6S ). Examination of GFAP expression in NFIA; NFIB double-homozygous embryos was not possible, because the two genes are closely linked, and the single-gene knockouts were independently generated. Thus, the partial reduction in GFAP expression in the single mutants likely reflects compensation by remaining NFI genes (see GOF data below). We next asked whether misexpression of NFIA/B is sufficient to promote precocious induction of GFAP, in vivo. Expression of GFAP in the embryonic chick neural tube is normally not detected until E10-E11 (Agius et al., 2004) . In embryos electroporated with NFIA or NFIB, by contrast, GFAP expression was observed as early as E7 ( Figures 6T-6Y and 6Z) . The GFAP + cells in these E7 embryos coexpressed exogenous mNFIA and mNFIB, (as detected by an HA epitope tag; Figures  6X and 6Y ), indicating that misexpression of these factors accelerates GFAP expression in a cell-autonomous manner. Taken together, these data suggest that NFIA/B not only control the initial specification of astroglial and oligodendroglial progenitors in the VZ but also play a later and selective role in terminal astrocyte differentiation.
Olig2 Antagonizes the Proastrocytic Function of NFIA/B
The initial requirement of NFIA for Olig2 expression in the VZ seemed paradoxical given the ability of NFIA/B to promote astrocyte differentiation and the fact that most Olig2 + glial progenitors are fated to become oligodendrocytes (Lu et al., 2002; Zhou and Anderson, 2002; Masahira et al., 2006) . One simple solution to this paradox would be that NFIA/B is selectively repressed in the oligodendrocyte lineage, at later stages of development. Indeed, while >90% of Olig2 + cells in the VZ are NFIA/B + at E12.5 ( Figures 7A-7D and 7I) , by E18.5 only w40% of Olig2 + cells are NFIA/B + ( Figures 7E-7I ). In Olig2 2/2 embryos, by contrast, most Olig2-GFP + cells continued to express NFIA/B at E18.5 ( Figures S5E-S5M ), reflecting the conversion of oligodendrocyte precursors (OPs) in these embryos to GFAP + astrocytes (Zhou and Anderson, 2002) . These data suggest that NFIA/B is indeed downregulated in at least some OPs following migration into the gray matter and suggest that Olig2 itself plays a role (directly or indirectly) in this repression.
Although loss of NFIA/B expression can account for w60% of the Olig2 + OPs at E18.5, the fate of the Olig2 + cells that continue to coexpress NFIA/B remained unclear. We reasoned that in many of these coexpressing cells, the proastrocytic function of NFIA/B might be inhibited. Since Olig2 normally suppresses astrocyte differentiation (Zhou and Anderson, 2002; Gabay et al., 2003; Fukuda et al., 2004) , we investigated whether Olig2 might functionally antagonize NFIA/B. To test this hypothesis, we first asked whether inclusion of excess Olig2 could block the ability of NFIA overexpression to accelerate the appearance of GFAP in vivo. Whereas electroporation of NFI genes alone caused an 11-to 12-fold increase in the number of GFAP-expressing cells in the chick embryonic spinal cord ( Figure 6Z ), coelectroporation with Olig2 suppressed this phenotype by w6-fold ( Figure 6Z , NFIA or B + Olig2). These data suggested that Olig2 can suppress or antagonize the ability of NFI genes to promote GFAP expression in vivo.
The complexity of the in vivo environment, as well as the time delay between electroporation (E2) and analysis (E7), made it difficult to exclude the possibility that the inhibitory influence of Olig2 on NFIA function in vivo reflected a non-cell-autonomous, or other indirect, effect. We therefore carried out analogous experiments in cultured rat E13.5 cortical progenitor cells grown in FGF-2 (Burrows et al., 1997; Gabay et al., 2003) . Overexpression of exogenous NFIA or NFIB in such cultures caused a >7-fold and 5-fold increase, respectively, in the proportion of transfected (GFP + ) cells coexpressing GFAP ( Figures 7K and 7M, arrows; Figure 7V ), consistent with our in vivo findings (Figure 6 ). Strikingly, cotransfection of Olig2 inhibited this proastrocytic effect of NFIA/B (Figures 7O and 7V) . Staining for neuronal markers indicated that the inhibitory effect of Olig2 on astrocyte differentiation was not due to any effect of Olig2 to promote neurogenesis or cell death (data not shown). Thus, Olig2 can block the ability of NFIA/B to promote GFAP expression in vitro, as well as in vivo ( Figure 6Z ).
Astrogliogenesis Depends on the Relative Levels of Olig2 and NFIA/B
The foregoing experiments suggested that Olig2 can suppress the proastrocytic activity of NFIA/B. To investigate whether this antagonism can be prevented by elevating the level of NFIA/B, we exploited the fact that transfection of Olig2 suppresses the spontaneous astrocyte differentiation caused by mitogen withdrawal from cultured E13.5 cortical progenitors (Gabay et al., 2003) . Immunostaining experiments confirmed that these progenitors express endogenous NFIA and NFIB (data not shown). If astrocyte differentiation in these cultures is promoted by endogenous NFIA/B, then one would predict that augmenting the levels of NFIA/B should override the antiastrocytic effect of Olig2 in this system.
To test this hypothesis, an Olig2 expression construct was transfected into E13.5 cortical progenitors alone or in combination with NFIA/B expression constructs. FGF-2 was withdrawn from the cultures to promote GFAP expression. In control cultures, under such conditions 55% of transfected (GFP Figure 7W , Olig2), confirming our previous report (Gabay et al., 2003) . By contrast, supplementation of Olig2 transfections with excess NFIA or NFIB restored the expression of GFAP to control levels (Figure 7U , arrows; Figure 7W , Olig2 + NFIA or + NFIB). These data suggest that increasing the total level of NFIA/B expression can override the suppression of astrocyte differentiation by Olig2 in vitro. Taken together, these in vitro data suggest that the suppression of NFIA function by Olig2 is dependent on the relative levels of these two factors.
Olig2 functions as a transcriptional repressor (Novitch et al., 2001; Zhou et al., 2001 ) and therefore could, in principle, directly repress NFIA transcription ( Figures  S5E-S5L) . However, such a mechanism cannot explain its ability to inhibit the proastroglial function of transfected NFIA, which is expressed under the control of a constitutive promoter. This latter inhibition could, therefore, be indirect, e.g., via transcriptional repression of a requisite NFIA cofactor. Alternatively, it could involve a direct, posttranscriptional inhibition of NFIA. As a first step toward distinguishing these alternatives, we investigated whether there might be a physical interaction between Olig2 and NFIA. Human embryonic kidney (HEK293) cells were cotransfected with Olig2 and NFIA expression constructs, each bearing distinct epitope tags. Extracts from these cells were immunoprecipitated with antibodies to the Olig2 or NFIA tag and Western blotted with antibodies to NFIA or the Olig2 tag, respectively. The results of this IP-Western experiment indicated that NFIA was found in Olig2 immunoprecipitates and vice versa ( Figure 7X , lane9-aNFIA and lane8-amyc). These data provide evidence of a physical association between the two proteins and suggest that the functional antagonism of NFIA by Olig2 is likely to involve a direct protein-protein interaction, rather than an indirect mechanism.
Discussion
Progenitor cells throughout the developing CNS undergo a developmental switch, during which they cease generating neurons and give rise to glia (Kessaris et al., 2001) . A fundamental unresolved issue has been the extent to which these two processes are intrinsically coupled by a single factor or are governed by distinct mechanisms ( Figure 1A ). Here we show that NFI transcription factors instruct glial-fate specification in vivo, but are unable to inhibit neurogenesis. Conversely, Notch effectors, while sufficient to inhibit neurogenesis, are insufficient to promote glial-fate specification. These data suggest that the abrogation of neurogenesis and the initiation of gliogenesis are controlled by genetically separable mechanisms. Nevertheless, the two processes are linked by the requirement of NFIA for the maintenance of Notch effector expression during the gliogenic phase ( Figures 8C and 8D ). This requirement allows NFIA to help maintain the undifferentiated progenitor pool that is the cellular substrate for gliogenesis. Thus, the gliogenic switch is controlled by a distributed, rather than a unitary, molecular mechanism ( Figure 9B ). This core mechanism initially operates in both astrocyte and oligodendrocyte progenitors ( Figure 9C, early) . At later stages, however, the function of NFIA/B must be antagonized in the oligodendrocyte lineage, because NFIA/B also promote terminal astrocyte differentiation. We show that this antagonism is mediated by Olig2 (Figure 9D , late) and is likely direct. These data suggest a transcriptional logic for the gliogenic switch that, initially, imposes an intrinsic astrocytic bias, which is ultimately overridden in the oligodendrocyte lineage by Olig2.
NFIA/B Are ''Pro-Glial'' Genes The JAK-STAT and the BMP/SMAD pathways have both been shown to promote expression of GFAP (Bonni et al., 1997; Nakashima et al., 1999) . However, GFAP is a late-appearing terminal astrocyte differentiation marker that is not expressed until w5 days after APs have migrated out of the VZ. Consistent with this, recent data indicate that, in murine spinal cord, phosphorylated (active) STAT3 is not strongly expressed in the gray matter until E17.5 (Yan et al., 2004) , the time at which GFAP is first detectable. It has been suggested that Sox9 may control the initiation of gliogenesis (Stolt et al., 2003) . However, misexpression of Sox9 in vivo does not cause precocious induction of GLAST in the VZ or premature emigration of APs (B.D. and D.J.A., unpublished data). To our knowledge, therefore, NFIA is the first transcription factor to be identified that is both necessary and sufficient to initiate glial-fate specification in the VZ and therefore qualifies as a ''pro-glial'' gene.
Because NFIA/B promote expression of GLAST in the VZ and because GLAST-expressing cells in the cortical VZ have been characterized as ''radial glia'' (Malatesta et al., 2000; Alvarez-Buylla et al., 2001; Gotz and Barde, 2005) , it could be argued that NFIA/B specify a ''radial glial'' phenotype. However, radial glial cell bodies are, by definition, located in the VZ, and misexpression of NFIA/B also promotes precocious emigration of APs into the gray matter (Figure 2 and Figure S2 ). Since migrating APs also express GLAST ( Figure S5 ), expression of GLAST is not a defining characteristic of radial glia. These data argue that NFIA/B initiate generic glial-fate specification in the spinal cord rather than promoting a radial glial phenotype.
NFIA Is Required to Maintain the Undifferentiated Progenitor Pool in the Spinal Cord
An unexpected result of the present studies is the observation that knock-down of NFIA caused the loss of expression of multiple markers of progenitors throughout the VZ, including Pax6, Pax7, Sox9, and Olig2. In the absence of NFIA, these progenitors eventually die. However, the loss of marker expression does not simply reflect cell death, since it is observed even when such death is attenuated by expression of the antiapoptotic protein p35. This phenotype is doubly striking, given that all of these markers are initially expressed prior to the induction of NFIA (Mansouri and Gruss, 1998; Briscoe et al., 2000; Kessaris et al., 2001) . These data reveal a fundamental, latent change in the mechanisms that regulate the expression of progenitor markers in the VZ, from NFIA-independent to NFIA-dependent.
Our data suggest that the requirement for NFIA in progenitor maintenance is mediated, at least in part, by its requirement for the continued expression of Notch effectors such as HES5. In the absence of NFIA, VZ progenitors differentiate inappropriately into neurons, a phenotype similar to that obtained by inhibiting Notch signaling with Su(H) DBM . Misexpression of HES, or of Notch ICD + Su(H), is sufficient to rescue this NFIA-RNAi phenotype, as well as to rescue the expression of progenitor markers ( Figures 8C and 8D ). In addition, misexpression of HES is sufficient to rescue the death of progenitors caused by NFIA knock-down, consistent with recent data demonstrating a role for Notch signaling in maintaining progenitor survival (Mason et al., 2006) . Importantly, however, misexpression of Notch effectors does not rescue the requirement of NFIA for induction of GLAST ( Figures 8A and 8D ). These data suggest that NFIA coordinates the transition from neurogenesis to gliogenesis via two distinct functions: a permissive requirement for the inhibition of neurogenesis, which maintains an undifferentiated progenitor pool, and the instructive promotion of a glial differentiation program ( Figure 9B) . Such a coordinated function for NFIA is logical, in retrospect. What is surprising is that the expression of HES genes in the VZ is initiated independently of NFIA (at E3-E4) but subsequently becomes dependent on this factor ( Figure 8C ). It is not clear whether this transition reflects a shift in HES regulation, from Notch-dependent to Notch-independent/NFIA-dependent, or simply the imposition of an additional requirement for NFIA. The upregulation of HES5 expression 1-2 days prior to induction of NFIA may serve to ensure that the inhibition of neurogenesis is well underway, before activation of the gliogenic program commences (Figure 8A, cE4 ; also see Figure 9A ). The subsequent shift to NFIA dependency may then provide that progenitors which express HES genes do not simply remain undifferentiated, but rather become specified for a glial fate.
NFIA/B Promote Terminal Astrocyte Differentiation
Previous studies have shown that adult mice deficient in NFIA or NFIB exhibit a reduction in cortical GFAP expression (das Neves et al., 1999; Steele-Perkins et al., 2005) , as well as a reduction in the number of midline glia (Shu et al., 2003) . It was not clear, however, whether this phenotype reflected a change in gene expression, cell death, or decreased astrocyte production. Our data indicate that misexpression of NFIA or NFIB is sufficient to accelerate GFAP expression in astrocytic precursors by several days, in vivo and in vitro. Furthermore, in E18.5 embryos lacking either NFIA or NFIB, a reduction in spinal cord GFAP expression was observed, without any change in the number of astrocytes (as measured by the expression of NFIB and NFIA, respectively). These data argue that NFIA/B promote the terminal differentiation of astrocytes, in addition to their earlier, pro-glial function. This role is likely to be direct, as functional NFI-binding sites have been found in the GFAP promoter (Cebolla and Vallejo, 2006) . It will be important in the future to determine the relationship between NFI genes and other regulators of GFAP expression, such as the JAK/STAT and BMP/SMAD pathways (Bonni et al., 1997; Nakashima et al., 1999) and DNA methylation (Takizawa et al., 2001; Fan et al., 2005) .
Olig2 Antagonizes the Proastrocytic Function of NFIA/B in the Oligodendrocyte Lineage While NFIA is required for the glial-fate specification of both oligodendrocyte and astrocyte progenitors in the VZ ( Figure 9C, early) , its later function to promote terminal differentiation is specific to the astroglial lineage. These observations raise the question of how NFIA/B can be initially required in the oligodendrocyte lineage, if they ultimately promote astrocyte differentiation. In a subset of OPs, NFIA/B are downregulated. Furthermore, Olig2 can antagonize the proastrocytic function of NFIA/B, when both factors are coexpressed. These data suggest that in OPs, the proastrocytic function of NFIA/B may be suppressed by Olig2 (Figure 9 , late). This antagonism is gene dosage-dependent, since elevating the level of NFIA/B can override the inhibition of astrocyte differentiation by Olig2. Therefore, we cannot exclude the possibility that elevated levels of NFIA/B override the effects of Olig2 and drive some OPs to an astrocytic fate. The dosage-sensitivity of Olig2-NFIA antagonism ( Figures 7V and 7W ) could explain why a small percentage of astrocytes are derived from Olig2 + progenitors in embryos in which one copy of Olig2 has been replaced by an inducible Cre recombinase lineage-tracer (Masahira et al., 2006) .
The mechanism of functional antagonism between NFIA and Olig2 is not yet clear. Our coimmunoprecipitation experiments indicate that these two proteins can physically associate, when cotransfected in cultured HEK cells. However, further experiments will be required to investigate the nature of the interaction between NFIA and Olig2, and its consequences for transcriptional regulation by these two proteins. Nevertheless, the observation that NFIA and Olig2 can physically associate suggests that the functional antagonism between these two proteins is likely to be direct rather than indirect.
Unitary versus Distributed Mechanisms of Glial-Fate Determination
The data presented here suggest that in vertebrates, the gliogenic switch is controlled by a distributed mechanism. The Notch pathway and its effectors function to suppress neurogenesis, while the pro-glial factors NFIA/B promote glial-fate specification. However, these two processes are coupled, via the requirement of NFIA for maintenance of Notch effector expression (Figure 9B) . Such a distributed mechanism may help to explain several areas of confusion in the literature. First, there have been conflicting reports as to whether misexpression of Notch effectors promotes gliogenesis or rather maintains progenitor status (reviewed in Louvi and Artavanis-Tsakonas, 2006) . One explanation for this discrepancy might be that if Notch effectors are misexpressed in a context where NFIA/B are expressed, then they will promote gliogenesis; alternatively, if NFIA/B are not yet expressed, then Notch effectors will inhibit differentiation and maintain progenitor status.
Second, there has been controversy about where and when cells expressing glial markers actually become committed to glial fate. In the adult subventricular zone, some GFAP + cells can generate neurons (Doetsch et al., 1999) . In the embryonic cortex, radial glia have been shown to generate neurons even after they express markers such as GLAST and brain lipid binding protein (Malatesta et al., 2000; Noctor et al., 2001; Anthony et al., 2004) ; reviewed in Gotz and Barde, 2005) . In the spinal cord, however, transplantation and other experiments have shown that Olig2 + cells are restricted to glial fates by the time they express GLAST (Richardson et al., 2000; Mukouyama et al., 2006) . Thus, not all GLAST + cells possess neurogenic capacity, and not all GFAP + cells are committed to a glial fate. A distributed mechanism such as we describe here could explain such context-dependent uncoupling between glial/radial glial marker expression and neurogenic capacity.
The mechanisms that control the loss of neurogenic capacity are not fully understood: for example, Notch signaling can either reversibly (Gaiano et al., 2000) or irreversibly (Morrison et al., 2000) inhibit neurogenesis; the difference between these two modes is not clear. Identification of the mechanisms that promote the irreversible loss of neurogenic capacity, and of the cues that promote expression of NFIA/B, should help to explain the relationship between the specification of glial identity and commitment to a glial fate. A deeper understanding of these mechanisms may, in turn, permit the controlled reversion of adult glial cells to neurogenic status for therapeutic purposes (Kondo and Raff, 2000) .
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